GlassScriptPhysician profile
John F Maddox
NPI 1477575868
$3,622.10
in general payments reported to CMS, 2019-2025
26 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $261 · 2021: $1,002 · 2022: $764 · 2023: $540 · 2024: $756 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $978.46 | 2020-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $592.32 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $270.15 | 2022-2023 | |
| Pfizer INC. | $231.75 | 2019-2024 | |
| Lilly USA, LLC | $226.61 | 2019-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $200.83 | 2020-2024 | Nexletol |
| Abbvie INC. | $193.39 | 2021-2025 | |
| Dexcom, INC. | $118.91 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Otsuka America Pharmaceutical, INC. | $114.44 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $93.60 | 2021-2024 | Trelegy Ellipta |
| Abbott Laboratories | $86.81 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $84.58 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $84.32 | 2021 | |
| Nevro Corp. | $47.32 | 2023-2024 | Senza |
| Amarin Pharma, INC. | $43.04 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.46 | 2022-2024 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $31.44 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.97 | 2022 | |
| Merck Sharp & Dohme LLC | $25.91 | 2019-2020 | |
| Nuvasive, INC. | $25.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.84 | 2020 | |
| Exact Sciences Corporation | $18.14 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $17.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Maddox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.